The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.
The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.
Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.
The two companies have established a broad framework that will enable them to collaborate on specific projects to develop NGS-based companion diagnostics.
The companies will combine MolecularMD's specialty diagnostic assays with Definiens' quantitative tissue read-outs to provide customized diagnostic solutions in oncology.
MolecularMD's assay will be used to select patients for a Phase II clinical trial in Europe to test an unspecified oncology therapy from Daiichi Sankyo.
The firm's NGS-based Notch 1 mutation detection test will be used to enroll patients in clinical trials.
The NGS laboratory has validated methods and platforms for circulating tumor DNA analysis.
NEW YORK (GenomeWeb News) – Molecular diagnostics company MolecularMD has received CLIA certification for its next-generation sequencing laboratory in Cambridge, Mass.
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.
The New York Times writes about the appearance of mosaicism in healthy people.
In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.